The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Lassa Fever Virus

Lassa fever is a zoonotic disease, caused by the Lassa fever virus. The animal reservoir of Lassa virus is a rodent commonly known as the ‘multimammate rat’. Mastomys rats infected with Lassa virus do not become ill, but can shed the virus in their urine and faeces. About 80% of people who become infected with Lassa virus have no symptoms. However, 1 in 5 infections result in severe disease, where the virus affects multiple organs such as the liver, spleen and kidneys.

The Native Antigen Company offer recombinant Lassa Fever virus antigens in support of vaccine research and development, and as targets for serological immunoassays.

Lassa Fever Virus Background

Lassa fever is a severe and sometimes fatal haemorrhagic disease caused by the Lassa fever virus (LAFV). First identified in 1969 in Nigeria, Lassa Fever virus is a single-stranded, enveloped RNA virus that belongs to the genus Mammarenavirus, of the Arenaviridae family of viruses. The natural reservoir for Lassa fever virus is the Mastomys natalensis rat and transmission of LAFV to humans most commonly occurs through contaminated rat urine and faeces. The virus is also spread by person-to-person via contact with contaminated human excreta, blood and bodily secretions, which causes a significant risk to health workers (1). LAFV is now endemic in West Africa and a substantial outbreak of Lassa fever in 2016 resulted in 160 deaths.

Most individuals infected with LAFV remain asymptomatic, but severe disease may occur in 15% of cases, with 1% of these resulting in death. Symptoms of LAFV infection are variable and non-specific, making early diagnosis difficult. The symptoms associated with Lassa fever range from mild fever, with headaches and fatigue, to severe life-threatening multiple organ failure. Early stages of the disease resemble symptoms of typhoid and malaria, making misdiagnosis is a risk (2).

Currently, no licensed vaccine is available for the prevention of Lassa fever. Early treatment is possible using the drug Ribavirin, but the similarity of Lassa Fever to other diseases may cause delay in the accurate diagnosis of LAFV infection. Diagnosis of LAFV can be performed using molecular techniques, but requires access to high containment facilities. Therefore, LAFV infection is commonly diagnosed using serological methods to detect virus-specific IgG or IgM in a patient’s serum. However, serological methods lack both sensitivity and specificity due to cross-reactivity with similar viruses, meaning that improved methods of diagnosis are urgently needed (3).

In 2015, a workshop organised by the WHO identified Lassa fever as an emerging disease requiring accelerated R&D to underpin in vitro diagnostic development, vaccine design and therapeutics. The Native Antigen Company supports the research areas highlighted in the WHO 2015 workshop report on emerging diseases, by supplying high quality products, suitable for LAFV research and in vitro diagnostic assay development.

References

  1. Viral hemorrhagic fever consortium
  2. World Health organization – media centre Lassa fever
  3. Racsa, L.D. et al (2016). Viral Hemorrhagic Fever Diagnostics. Clin Infect Dis. 62: 214–219.

Lassa Fever Antigens

Our recombinant Lassa Fever virus proteins are produced using mammalian and E. coli expression systems and are suitable for use in assay development, vaccine research and as antigens for the preparation of antibodies. These proteins are presented as either His-tagged or Fc-fusion proteins, with an option of either human, sheep or mouse Fc regions to maximise flexibility.

Lassa Fever Antibodies

The Native Antigen Company provides three mouse monoclonal antibodies specific to Lassa Fever virus GP1 and GP2 which are ideal for use in a wide range of research studies and immunoassay development.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Monkeypox; 3 months on

It has been 3 months since a new, unusually widespread outbreak of Monkeypox was first identified. What was normally a virus confined to limited infections in the West African continent is becoming a global health concern.   What have we learned about this virus...

COVID-19 Underlines the Need for Universal Vaccines

This article was originally published on Clinical Lab Manager. In recent history, humanity has witnessed numerous emerging viral diseases, including the SARS, MERS, and SARS-2 coronaviruses, as well as HIV, Zika, Ebola, and H1N1 and H3N2 influenza. None have tested...

Tick-Borne Diseases: The Need for Integrated Approaches to Human-Animal Diagnosis

This article has been published in Volume 8, Issue 3 of International Animal Health Journal. Ticks are responsible for a diverse group of neglected, and rapidly expanding diseases, affecting humans, companion animals and livestock. A growing understanding of tick-host...

The Continued Challenges of Flavivirus Serology

This article was originally published on the Science Advisory Board. Flaviviruses are a genus of positive-sense RNA viruses, largely transmitted by mosquito and tick vectors that cause infections, including yellow fever, dengue, the Zika virus, West Nile virus,...

The Role of Serology in Tracking COVID-19 Mutations

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

1 + 5 =